Compare
Brainstorm Cell Therapeutics Inc. vs Abpro Holdings, Inc. vs Zeo ScientifiX, Inc. vs Adaptin Bio, Inc.
| Latest fiscal year | Brainstorm Cell Therapeutics Inc. BCLI | Abpro Holdings, Inc. ABPO | Zeo ScientifiX, Inc. ZEOX | Adaptin Bio, Inc. APTN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-10-31 | 2025-12-31 |
| Revenue | n/a | n/a | $5.20M | n/a |
| Revenue growth (YoY) | n/a | n/a | +12.5% | n/a |
| Gross margin | n/a | n/a | 82.1% | n/a |
| Operating margin | n/a | n/a | -103.6% | n/a |
| Net margin | n/a | n/a | -106.2% | n/a |
| Net income | -$10.31M | -$2.89M | -$5.52M | -$5.17M |
| EPS (Diluted) | -$1.11 | -$1.30 | -$0.86 | -$0.66 |
| Operating cash flow | -$6.97M | -$6.01M | -$718.0K | -$4.78M |
| Free cash flow | n/a | n/a | -$741.0K | n/a |
| Cash & equivalents | $29.0K | n/a | n/a | $459.2K |
| Total assets | $1.02M | $1.06M | $1.53M | $619.2K |
| Total liabilities | $11.01M | n/a | $2.95M | $2.11M |
| Shareholders' equity | -$9.98M | -$8.83M | -$1.42M | -$1.49M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 11.03M | 2.73M | 6.75M | 8.66M |
Revenue, most recent five fiscal years
| Fiscal year | Brainstorm Cell Therapeutics Inc. | Abpro Holdings, Inc. | Zeo ScientifiX, Inc. | Adaptin Bio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $183.0K Ended 2024-12-31 | $5.20M Ended 2025-10-31 | n/a |
| 1 year earlier | n/a | $122.0K Ended 2023-12-31 | $4.62M Ended 2024-10-31 | n/a |
| 2 years earlier | n/a | n/a | $4.56M Ended 2023-10-31 | n/a |
| 3 years earlier | n/a | n/a | $6.49M Ended 2022-10-31 | n/a |
| 4 years earlier | n/a | n/a | $5.60M Ended 2021-10-31 | n/a |